

CALL FOR POSTERS ABSTRACTS

SUBMISSION DEADLINE: MONDAY, August 28

DIA Oligonucleotide-Based Therapeutics Conference

OCTOBER 25-27 | NORTH BETHESDA, MD

**CALL FOR POSTER ABSTRACTS**

POSTER ABSTRACT SUBMISSION DETAILS and GUIDELINES

SUBMISSION DEADLINE: MONDAY, AUGUST 28

Poster Submission Overview and Topics

Please submit your poster abstracts based on the primary interest area topics, listed within the right column, in support of the following core interest areas: Nonclinical, Clinical, and CMC.

Nonclinical

The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics.

Clinical Development

These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics.

Chemistry, Manufacturing, and Controls (CMC)

The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies.

Did you know submitting an abstract to a DIA conference leads to a potential publication in *Therapeutic Innovation & Regulatory Science* (TIRS), DIA's peer-reviewed, scientific journal? All submitted abstracts will be considered for publication, as an invited communication.

TIRS advances health care product discovery, development, regulation, and use through the publication of peer-reviewed articles and commentaries which convert biomedical science into practical solutions to advance human health.

Poster submissions may include the following oligonucleotide-related topics:

- Assay Development and Optimization
- Clinical Pharmacology, including Oligonucleotide ADME
- Clinical Safety
- Formulations
- Hot Topics in Oligonucleotide Research
- Impurities
- Manufacturing
- Miscellaneous
- Nonclinical Efficacy Models
- Toxicology, including updates in Oligo-Toxicology (clinical and nonclinical)
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Oligonucleotide Conjugation and Tissue Targeting
- Regulatory Affairs, including Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for:
 - Rare Diseases
 - Immunoncology
 - Metabolic Diseases
 - Neuromuscular Conditions
- Targeting and Delivery, including Target Identification Screening Methods (Discovery)
- Translational Experience

Poster Abstract Submission Deadline: Monday, August 28**Notification:** Week of September 5**Conference Dates:** October 25-27**Location:** Bethesda North Marriott Hotel and Conference Center**Poster Session:** October 25 from 4:30-5:30PM**Poster Set Up:** October 25 (time to be determined)**Please submit all abstracts online at:** DIAglobal.org/Abstract

General Submission Requirements

(Please read the following instructions carefully, incorrect or incomplete abstracts will not be considered.)

1. All abstracts must be submitted online to **DIAGlobal.org/Abstract**
2. Title must reflect the abstract content accurately and concisely.
3. All poster presentations must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of brand names in any area of the poster, including poster titles and/or handouts. Logos and advertising may not appear anywhere on the poster.
4. Posters must be original in research and include appropriate empirical evidence.
5. Posters must include data (i.e. research results and conclusion) for consideration.
6. Preliminary/pilot data is acceptable.
7. Abstracts submitted for presentation should not have been presented or published previously.

Onsite Requirements

- If an abstract is accepted, the primary author is required to pay the applicable conference registration fee, related expenses, and must be onsite at the meeting during the designated poster session time.

Please note that an individual may only be primary author on one poster.

- Co-authors who would like to be present for your session must register as well. If none of the authors are able to attend the conference, your poster must be withdrawn from the program.
- Presenters must organize and pay for all shipping arrangements for their poster materials. DIA will not ship or store any materials.
- Presenters must prepare a poster to fit a 4'x 8' poster board.

Eligibility

- Individuals eligible to submit a professional poster include post-doctoral scholars, medical residents, fellows, and professionals whose affiliation is consistent with the mission of DIA.

Required Documentation For All Abstracts

• Participant Disclosure Information:

All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program.

- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted posters will be available on DIA's website for attendee download after the event.

SUBMISSION GUIDELINES

The following information will be requested at the time of submission.

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Submitter or Author Information

Prefix:	Country:
First Name:	Address Line:
Middle Name:	City:
Last Name:	State/Province:
Name Suffix:	Zip/Postal Code:
Degrees:	Phone:
Job Title:	Email:
Company:	

NOTE: If you are submitting on behalf of author, you are considered the SUBMITTER and will need to complete the required information for yourself AND ALSO for the AUTHOR. Submitters will be the contact for author regarding the status of the abstract.

Abstract Title (maximum 125 characters, including spaces)

Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the poster.

Primary interest Area

Select the interest area that best relates to your abstract.

Keyword (Maximum 100 characters including spaces)

One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

Objective (Maximum 300 characters including spaces)

Please provide a one sentence statement of the objective of the abstract.

Method (Maximum 300 characters including spaces)

When, where, and how was the study done? What materials were used or who was included in the study?

Results (Maximum 2000 characters including spaces)

What quantitative data was collected? What answer was found to the research question? What did the study find? Was the tested hypothesis true?

Conclusion (Maximum 2000 characters including spaces)

State what can be concluded from the study and its implications.

Abstracts will be reviewed, and authors will be notified of results the week of September 5